Assessing Quality of Life in Patients Undergoing Allogeneic Stem Cell Transplantation

Share this content:

the Cancer Therapy Advisor take:

Health-related quality of life (HRQL) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was linked to whether the transplant was after myeloablative conditioning (MAC) or reduced intensity conditioning (RIC), according to an article posted online in the European Journal of Cancer Care.

Participants included 94 patients who were undergoing HSCT after MAC (n = 18) or RIC (n= 76).  The EORTC QLQ C-30 was used to assess HRQL in patients during the inpatient period and throughout the following 3 years.

Patients’ functional status and global quality of life (eg, role,social functions) were observed to have decreased from baseline to weeks 2 and 3.

Symptoms including appetite loss, nausea and vomiting, diarrhea and fatigue significantly increased during the first 3 weeks.

HRQL took at least 1 year to return to baseline level, but only role function was found to have significantly improved 3 years post-transplantation.

Patients who initially received MAC had a significantly worse HRQL at baseline, along with patients with extensive chronic graft-versus-host disease.   Patients who received MAC also experienced more pain, interrupted sleep, and appetite loss in weeks 3 and 4 compared to those who received RIC.  

Cognition Impaired in Some Breast Cancer Patients
Quality of life linked to whether the transplant was after myeloablative conditioning or reduced intensity conditioning.
Health-related quality of life was evaluated in 94 patients undergoing allogeneic haematopoietic stem cell transplantation after myeloablative or reduced intensity conditioning.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs